Dalmia Healthcare starts clinical trials to study efficacy of ayurvedic drug for COVID-19

All regulatory guidelines will be followed to conduct the multi-centric, Phase III clinical trials, the Dalmia Group firm said in a statement. "We are conducting human trials of our highly efficient ayurvedic composition which can potentially help in curing COVID-19 patients," Dalmia Group of Companies Chairman Sanjay Dalmia said.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2U5rqr6
via IFTTT